达格列净应用慢性肾脏病治疗研究进展
Research Progress on the Application of Dapagliflozin in the Treatment of Chronic Kidney Disease
DOI: 10.12677/ACM.2024.141316, PDF,    科研立项经费支持
作者: 汪水发：景德镇市第三人民医院肾内科，江西 景德镇；徐承云*：南昌大学第二附属医院肾内科，江西 南昌
关键词: 达格列净；钠–葡萄糖协同转运蛋白2抑制剂；糖尿病肾脏病；非糖尿病肾脏病；临床疗效；作用机制；Dapagliflozin； Sodium-Glucose Cotransporter 2 Inhibitor； Diabetic Nephropathy； Non-Diabetic Nephropathy； Clinical Efficacy； Mechanism of Action
摘要: 目前，慢性肾脏病已成为全球严峻的健康挑战，其患病率和死亡率持续攀升。在我国，慢性肾脏病患者数量众多，然而可用的治疗手段却相对有限。近期研究指出，达格列净不仅是一种出色的血糖调节药物，同时可以降低心血管不良事件的发生风险，并能推迟糖尿病肾脏疾病的进展。在非糖尿病肾脏病的慢性肾脏病患者中也观察到肾脏获益。本文系统性地总结了达格列净在慢性肾脏病治疗中的最新研究进展和临床应用现状，对达格列净对慢性肾脏病患者的治疗策略、用药原则和潜在效果提供了理论基础，推动达格列净在慢性肾脏病中的进一步应用和开发。
Abstract: At present, chronic kidney disease (CKD) is a serious global health problem, and its morbidity and mortality are increasing. There are many patients in our country, and the means of treatment are limited. Recently, it has been found that dapagliflozin is not only a good hypoglycemic drug, but also can reduce cardiovascular adverse events and delay the onset of diabetic nephropathy (DN). Renal benefits have also been observed in patients with non-diabetic nephropathy. This article systemat-ically summarizes the latest research progress and clinical application status of dapagliflozin in the treatment of chronic kidney disease, provides a theoretical basis for the treatment strategy, medi-cation principles and potential effects of dapagliflozin in patients with chronic kidney disease, thereby advancing further application and development in the field of chronic kidney disease.
文章引用：汪水发, 徐承云. 达格列净应用慢性肾脏病治疗研究进展[J]. 临床医学进展, 2024, 14(1): 2255-2260. https://doi.org/10.12677/ACM.2024.141316

参考文献

[1] Kong, J., Li, L., Yuan, H., et al. (2023) In Silico Discovery of Potential Sodium—Glucose Cotransporter-2 Inhibitors from Natural Products for Treatment of Heart Failure via Molecular Docking and Molecular Dynamics Simulation Ap-proach. Journal of Biomolecular Structure and Dynamics, 41, 8109-8120. [Google Scholar] [CrossRef] [PubMed]
[2] Tuttle, K.R. (2023) Digging Deep into Cells to Find Mecha-nisms of Kidney Protection by SGLT2 Inhibitors. Journal of Clinical Investigation, 133, E167700. [Google Scholar] [CrossRef] 
[3] Wheeler, D.C., StefÁNsson, B.V., Jongs, N., et al. (2021) Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 22-31. [Google Scholar] [CrossRef] 
[4] Zhou, Y., Wang, F., Wen, F., et al. (2023) The SGLT2i-Mediated Regulation of Cardiovascular and Safety Outcomes among Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [Google Scholar] [CrossRef] 
[5] 刘姗姗, 赵璨, 罗力亚. 达格列净治疗老年2型糖尿病并心力衰竭患者的临床疗效及其对心功能的影响[J]. 实用心脑肺血管病杂志, 2022, 30(3): 107-111.
[6] 余蓓蕾, 姜玲, 李喆, 等. 肾小球滤过率对急慢性肾脏病患者溶质及电解质肾脏排泄分数的影响[J]. 肾脏病与透析肾移植杂志, 2023, 32(1): 1-7.
[7] Li, Y., Ning, Y., Shen, B., et al. (2023) Temporal Trends in Prevalence and Mortality for Chronic Kidney Disease in China from 1990 to 2019: An Analysis of the Global Burden of Disease Study 2019. Clinical Kidney Journal, 16, 312-321. [Google Scholar] [CrossRef] [PubMed]
[8] Khadilkar, A., Oza, C. and Mondkar, S.A. (2023) Insulin Resistance in Adolescents and Youth with Type 1 Diabetes: A Review of Problems and Solutions. Clinical Medi-cine Insights: Endocrinology and Diabetes, 16. [Google Scholar] [CrossRef] [PubMed]
[9] 王丽, 苏钢, 洪娟, 等. 达格列净对早期糖尿病肾病的疗效观察[J]. 中国医师进修杂志, 2023, 46(10): 930-933. [Google Scholar] [CrossRef] 
[10] 储帆, 梁伟, 刘子康, 等. 达格列净治疗不同肾功能状态糖尿病肾脏疾病患者水肿的疗效与安全性分析[J]. 临床肾脏病杂志, 2023, 23(7): 575-584.
[11] Groop, P.H., Dandona, P., Phillip, M., et al. (2020) Effect of Dapagliflozin as an Adjunct to Insulin over 52 Weeks in Individu-als with Type 1 Diabetes: Post-Hoc Renal Analysis of the DEPICT Randomised Controlled Trials. The Lancet Diabetes & Endocrinology, 8, 845-854. [Google Scholar] [CrossRef] 
[12] Mathieu, C., Rudofsky, G., Phillip, M., et al. (2020) Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-Week Results from a Randomized Controlled Trial. Diabetes, Obesity and Metabo-lism, 22, 1516-1526. [Google Scholar] [CrossRef] [PubMed]
[13] Janković, A., Dimković, N., Todorov-Sakić, V., et al. (2023) Presence of Non-Diabetic Kidney Diseases in Biopsy Specimens of Diabetic Patients’ Single Center Experience. International Journal of Molecular Sciences, 24, Article 14759. [Google Scholar] [CrossRef] [PubMed]
[14] Cherney, D.Z.I., Dekkers, C.C.J., Barbour, S.J., et al. (2020) Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial. The Lancet Diabetes & Endocrinology, 8, 582-593. [Google Scholar] [CrossRef] 
[15] Gohda, T. and Murakoshi, M. (2022) Sodium-Glucose Co-transporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. International Journal of Molecular Sciences, 23, Article 13749. [Google Scholar] [CrossRef] [PubMed]
[16] Rossing, P., Inzucchi, S.E., Vart, P., et al. (2022) Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials. The Lancet Diabetes & Endocrinology, 10, 24-34. [Google Scholar] [CrossRef] 
[17] Schechter, M., Jongs, N., Chertow, G, M., et al. (2023) Ef-fects of Dapagliflozin on Hospitalizations in Patients with Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD. Annals of Internal Medicine, 176, 59-66. [Google Scholar] [CrossRef] 
[18] McEwan, P., Darlington, O., Miller, R., et al. (2022) Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clinical Jour-nal of the American Society of Nephrology, 17, 1730-1741. [Google Scholar] [CrossRef] 
[19] Wheeler, D.C., Jongs, N., Stefansson, B.V., et al. (2022) Safety and Efficacy of Dapagliflozin in Patients with Focal Segmental Glomerulosclerosis: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kid-ney Disease (DAPA-CKD) Trial. Nephrology Dialysis Transplantation, 37, 1647-1656. [Google Scholar] [CrossRef] [PubMed]
[20] Heerspink, H.J.L., Cherney, D., Postmus, D., et al. (2022) A Pre-Specified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Randomized Controlled Trial on the Incidence of Abrupt Declines in Kidney Function. Kidney Interna-tional, 101, 174-184. [Google Scholar] [CrossRef] [PubMed]
[21] Chertow, G.M., Correa-Rotter, R., Vart, P., et al. (2023) Effects of Dapagliflozin in Chronic Kidney Disease, with and without Other Cardiovascular Medications: DAPA-CKD Trial. Journal of the American Heart Association, 12, e028739. [Google Scholar] [CrossRef] 
[22] 张青青, 刘珊珊, 王英惠, 等. 达格列净治疗慢性肾脏病的研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(5): 388-392.
https://Doi.Org/10.3969/J.Issn.2097-0005.2022.05.014
[23] Bonnet, F. and Scheen, A, J. (2018) Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complica-tions and Cardiovascular Disease. Diabetes & Metabolism, 44, 457-464. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, F., Zhao, Y., Wang, Q., et al. (2019) Dapagliflozin At-tenuates Renal Tubulointerstitial Fibrosis Associated with Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. Frontiers in Endocrinology, 10, Article 441. [Google Scholar] [CrossRef] [PubMed]
[25] Hodrea, J., Balogh, D.B., Hosszu, A., et al. (2020) Reduced O-GlcNAcylation and Tubular Hypoxia Contribute to the Antifibrotic Effect of SGLT2 Inhibitor Dapagliflozin in the Diabetic Kidney. American Journal of Physiology-Renal Physiology, 318, F1017-F1029. [Google Scholar] [CrossRef] [PubMed]
[26] Shibusawa, R., Yamada, E. and Okada, S. (2019) Dapagliflozin Rescues Endoplasmic Reticulum Stress-Mediated Cell Death. Scientific Reports, 9, Article No. 9887. [Google Scholar] [CrossRef] [PubMed]
[27] Elkazzaz, S.K., Khodeer, D.M., El Fayoumi, H.M. and Moustafa, Y.M. (2021) Role of Sodium Glucose Cotransporter Type 2 Inhibitors Dapagliflozin on Diabetic Nephropathy in Rats; Inflammation, Angiogenesis and Apoptosis. Life Sciences, 280, Article ID: 119018. [Google Scholar] [CrossRef] [PubMed]
[28] Jaikumkao, K., Pongchaidecha, A., Chueakula, N., et al. (2018) Dapagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, Slows the Progression of Renal Complications through the Suppression of Renal Inflammation, Endoplasmic Reticulum Stress and Apoptosis in Prediabetic Rats. Diabetes, Obesity and Metabolism, 20, 2617-2626. [Google Scholar] [CrossRef] [PubMed]
[29] Baer, P.C., Koch, B., Freitag, J., et al. (2020) No Cytotoxic and Inflam-matory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions in Vitro. International Journal of Molecular Sciences, 21, Article 391. [Google Scholar] [CrossRef] [PubMed]
[30] Lupsa, B.C. and Inzucchi, S.E. (2018) Use of SGLT2 Inhibitors in Type 2 Diabetes: Weighing the Risks and Benefits. Diabetologia, 61, 2118-2125. [Google Scholar] [CrossRef] [PubMed]
[31] 曹丹, 张桂红, 赵钰. 达格列净在早期2型糖尿病肾病中的应用及对肾功能的影响分析[J]. 糖尿病新世界, 2023, 26(8): 106-108.
[32] Hallow, K.M., Boulton, D.W., Penland, R.C., et al. (2020) Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeu-tics, 375, 76-91. [Google Scholar] [CrossRef] [PubMed]
[33] Van Bommel, E.J.M., Muskiet, M.H.A., Van Baar, M.J.B., et al. (2020) The Renal Hemodynamic Effects of the SGLT2 Inhibitor Dapagliflozin Are Caused by Post-Glomerular Vasodilatation Rather than Pre-Glomerular Vasoconstriction in Metformin-Treated Patients with Type 2 Diabetes in the Randomized, Double-Blind RED Trial. Kidney International, 97, 202-212. [Google Scholar] [CrossRef] [PubMed]

为你推荐